成人低级别胶质瘤的最新进展与未来方向:神经肿瘤学会(SNO)与欧洲神经肿瘤协会(EANO)共识
该共识综述了成人低级别胶质瘤的分子神经病理学进展,指出大多数II级和III级胶质瘤存在IDH突变且预后相对良好。文章讨论了基于IDH和1p/19q状态的肿瘤再分类,以及甲基化分析和CDKN2A/2B缺失分析的可能作用,并总结了手术切除、神经影像(包括2-羟基戊二酸磁共振波谱和氨基酸PET)及放化疗的研究进展。
要点
- 多数II级和III级胶质瘤存在IDH突变,预后相对良好且两个级别相似。
- 基于IDH和1p/19q状态的分子分类将低级别胶质瘤与IDH野生型胶质瘤区分。
- 先进影像技术如2-羟基戊二酸磁共振波谱和氨基酸PET扫描与分子亚型相关。
研究设计与样本
- 由神经肿瘤学会(SNO)与欧洲神经肿瘤协会(EANO)发布的共识,综述成人低级别胶质瘤的最新进展与未来方向。
主要发现
- 大多数II级和III级胶质瘤存在IDH突变,在两个肿瘤级别中均提示相对良好且相似的预后。
- IDH突变型低级别胶质瘤与IDH野生型胶质瘤(大多数胶质母细胞瘤的代表)代表根本不同的实体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The finding that most grades II and III gliomas harbor isocitrate dehydrogenase (IDH) mutations conveying a relatively favorable and fairly similar prognosis in both tumor grades highlights that these tumors represent a fundamentally different entity from IDH wild-type gliomas exemplified in most glioblastoma. Herein we review the most recent developments in molecular neuropathology leading to reclassification of these tumors based upon IDH and 1p/19q status, as well as the potential roles of methylation profiling and deletional analysis of cyclin-dependent kinase inhibitor 2A and 2B. We discuss the epidemiology, clinical manifestations, benefit of surgical resection, and neuroimaging features of lower-grade gliomas as they relate to molecular subtype, including advanced imaging techniques such as 2-hydroxyglutarate magnetic resonance spectroscopy and amino acid PET scanning. Recent, ongoing, and planned studies of radiation therapy and both cytotoxic and targeted chemotherapies are summarized, including both small molecule and immunotherapy approaches specifically targeting the mutant IDH protein.
引用
- Schiff D, Van den Bent M, Vogelbaum MA, et al. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. Neuro Oncol. 2019. PMID: 30753579. doi:10.1093/neuonc/noz033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。